VALVULAR AND STRUCTURAL HEART DISEASES Original Studies Left Atrial Appendage Closure With Amplatzer Cardiac Plug in Atrial Fibrillation: Initial European Experience

Background: In most patients with atrial fibrillation (AF) and stroke, there is thrombotic embolization from the left atrial appendage (LAA). Percutaneous closure of the LAA is a novel alternative for the treatment of patients with AF at a high risk of stroke, in whom long-term anticoagulation therapy is not possible or not desired. This study details the initial experience with the Amplatzer Cardiac Plug (ACP) in humans. Methods: Investigator-initiated retrospective preregistry data collection to evaluate procedural feasibility and safety up to 24 hr after implantation of the ACP, a nitinol device designed for percutaneous trans-septal implantation in LAA of patients with paroxysmal, permanent, or persistent AF. Results: In 137 of 143 patients, LAA occlusion was attempted, and successfully performed in 132 (96%). There were serious complications in 10 (7.0%) patients (three patients with ischemic stroke; two patients experienced device embolization, both percutaneously recaptured; and five patients with clinically significant pericardial effusions). Minor complications were insignificant pericardial effusions in four, transient myocardial ischemia in two, and loss of the implant in the venous system in one patient. Conclusion: The implantation of the ACP device is a feasible method for percutaneous occlusion of the LAA. VC 2011 Wiley-Liss, Inc.

[1]  Rahul Wadke,et al.  Atrial fibrillation. , 2022, Disease-a-month : DM.

[2]  B. Leithäuser,et al.  Left atrial appendage closure with Amplatzer Cardiac Plug for prevention of stroke in atrial fibrillation: in-vivo imaging. , 2011, Journal of Cardiovascular Medicine.

[3]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[4]  R. Schwartz,et al.  Left Atrial Appendage Occlusion Eliminates the Need for Warfarin , 2009, Circulation.

[5]  J. Healey,et al.  Left Atrial Appendage Occlusion Does Not Eliminate the Need for Warfarin , 2009, Circulation.

[6]  B. Leithäuser,et al.  Cardioembolic Stroke in Atrial Fibrillation-Rationale for Preventive Closure of the Left Atrial Appendage , 2009, Korean circulation journal.

[7]  E. Hylek.  Antithrombotic prophylaxis in elderly patients with atrial fibrillation. , 2009, Seminars in Thrombosis and Hemostasis.

[8]  D. Singer,et al.  The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation , 2009, Annals of Internal Medicine.

[9]  Maurice Buchbinder,et al.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial , 2009, The Lancet.

[10]  H. Aberg.  Atrial fibrillation. I. A study of atrial thrombosis and systemic embolism in a necropsy material. , 2009, Acta medica Scandinavica.

[11]  W. Baker,et al.  Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States , 2009, Journal of managed care pharmacy : JMCP.

[12]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[13]  A. Walker,et al.  Epidemiology and outcomes in patients with atrial fibrillation in the United States. , 2008, Heart rhythm.

[14]  M. Aguilar,et al.  Anticoagulation in atrial fibrillation: selected controversies including optimal anticoagulation intensity, treatment of intracerebral hemorrhage , 2008, Journal of Thrombosis and Thrombolysis.

[15]  S. Middleton,et al.  Barriers to the Use of Anticoagulation for Nonvalvular Atrial Fibrillation: A Representative Survey of Australian Family Physicians , 2008, Stroke.

[16]  G. Lip,et al.  Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial , 2007, The Lancet.

[17]  J. Halperin,et al.  Left atrial appendage closure for stroke prevention in atrial fibrillation: state of the art and current challenges , 2007, Nature Clinical Practice Cardiovascular Medicine.

[18]  G. Schuler,et al.  Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. , 2007, Journal of the American College of Cardiology.

[19]  O. Onalan,et al.  Left Atrial Appendage Exclusion for Stroke Prevention in Patients With Nonrheumatic Atrial Fibrillation , 2007, Stroke.

[20]  OrhanOnalan,et al.  Left Atrial Appendage Exclusion for Stroke Prevention in Patients With Nonrheumatic Atrial Fibrillation , 2007 .

[21]  Silvia G. Priori,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text , 2006 .

[22]  E. Hylek,et al.  Translating the Results of Randomized Trials into Clinical Practice: The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation , 2006, Stroke.

[23]  E. Lonn,et al.  Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. , 2005, American heart journal.

[24]  G. Lip,et al.  Atrial Fibrillation and the Hypercoagulable State: From Basic Science to Clinical Practice , 2003, Pathophysiology of Haemostasis and Thrombosis.

[25]  I. Palacios,et al.  Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[26]  M. Lesh,et al.  Percutaneous Left Atrial Appendage Transcatheter Occlusion to Prevent Stroke in High-Risk Patients With Atrial Fibrillation: Early Clinical Experience , 2002, Circulation.

[27]  A. Laupacis,et al.  Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation. , 2002, Archives of internal medicine.

[28]  S. Jackson,et al.  Doctors’ beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention , 2002, Internal medicine journal.

[29]  M. Rich,et al.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.

[30]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[31]  C. Stone,et al.  The left atrial appendage: our most lethal human attachment! Surgical implications. , 2000, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[32]  T Fahey,et al.  The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. , 2000, BMJ : British Medical Journal.

[33]  F. McAlister,et al.  Why do patients with atrial fibrillation not receive warfarin? , 2000, Archives of internal medicine.

[34]  D. Singer,et al.  Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study , 1999, Annals of Internal Medicine.

[35]  A. Camm,et al.  Left atrial appendage: structure, function, and role in thromboembolism , 1999, Heart.

[36]  W. Edwards,et al.  Thoracoscopic obliteration of the left atrial appendage: potential for stroke reduction? , 1996, The Annals of thoracic surgery.

[37]  J. Odell,et al.  Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. , 1996, The Annals of thoracic surgery.

[38]  W. Manning,et al.  Accuracy of Transesophageal Echocardiography for Identifying Left Atrial Thrombi: A Prospective, Intraoperative Study , 1995, Annals of Internal Medicine.

[39]  D. Leung,et al.  Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. , 1994, Journal of the American College of Cardiology.

[40]  J. Greenfield,et al.  Compliance of left atrium with and without left atrium appendage. , 1990, The American journal of physiology.

[41]  Palle Petersen,et al.  PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.

[42]  E. Benjamin,et al.  Status of the epidemiology of atrial fibrillation. , 2008, The Medical clinics of North America.

[43]  J. Cavalcante,et al.  Examining warfarin underutilization rates in patients with atrial fibrillation: Detailed chart review essential to capture contraindications to warfarin therapy , 2008 .

[44]  M. O’Donnell,et al.  Pre-admission warfarin use in patients with acute ischemic stroke and atrial fibrillation: The appropriate use and barriers to oral anticoagulant therapy. , 2007, Thrombosis research.

[45]  R. Abbate,et al.  Risk of bleeding in very old atrial fibrillation patients on warfarin: relationship with ageing and CHADS2 score. , 2007, Thrombosis research.

[46]  J. Halperin,et al.  Obliteration of the left atrial appendage for prevention of thromboembolism. , 2003, Journal of the American College of Cardiology.

[47]  N. Ammash,et al.  Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. , 1995, Journal of the American College of Cardiology.

[48]  R. Walsh,et al.  Altered left atrial compliance after atrial appendectomy. Influence on left atrial and ventricular filling. , 1993, Circulation research.